Breast Tumor Clinical Trial
Major Aims of study:
1. To create a gene expression-based prognostic device that complements or exceeds the
prognostic utility of conventional biomarkers of breast cancer outcome.
2. To identify one or more clinical subgroups of patients for which the prognostic device
outperforms, or substantially adds to, the prognostic performance of conventional
markers that currently determine therapeutic strategies.
Sub-Aims of study:
1. Assess the prognostic value of the multiple gene expression signatures, alone and in
combination, using a large cohort of breast cancer patients for which pathology,
treatment and outcome is available. A "training" and "testing" design is proposed.
2. Evaluate the utility of a prognostic device that measures gene expression levels from
formalin-fixed paraffin-embedded specimens (FFPEs) of primary resected tumors. The
investigators will utilize the Affymetrix Quantigene 2.0 Assay and/or the Illumina
BeadXpress VeraCode DASL Gene Expression Assay (FDA-approved IVDMIA.)
3. For specific clinical subgroups of patients/tumors, the investigators will
mathematically identify additive or synergistic prognostic relationships between genes
and gene signatures that, in combination, will yield maximal risk prediction (distant
metastases-free survival) for patients.
4. Compare the prognostic utility of the investigators device to that of the conventional
prognostic variables that are currently used to determine therapeutic strategy.
5. Incorporate the prognostic signatures into a practical prognosis algorithm that seeks
to include conventional measures of outcome such as tumor size, histologic grade, nodal
status, patient age, or Nottingham index, etc.
The investigators hypothesize that adequate quality and quantity of tumor RNA may be
extracted from archival paraffin-embedded tumor specimens for gene expression profiling, and
that archival tumor-derived genomic signatures may be used as prognosticators or predictors
in breast cancer.
Status | Active, not recruiting |
Enrollment | 0 |
Est. completion date | December 2014 |
Est. primary completion date | December 2014 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | N/A and older |
Eligibility |
Inclusion Criteria: - Eligible patients should have at least 5 years' follow-up at NUH and have an available archival paraffin-embedded tumor block stored at the Department of Pathology, NUH Exclusion Criteria: - Non breast cancer patients |
Observational Model: Cohort, Time Perspective: Retrospective
Country | Name | City | State |
---|---|---|---|
Singapore | National University Hospital | Singapore |
Lead Sponsor | Collaborator |
---|---|
National University Hospital, Singapore |
Singapore,
Slodkowska EA, Ross JS. MammaPrint 70-gene signature: another milestone in personalized medical care for breast cancer patients. Expert Rev Mol Diagn. 2009 Jul;9(5):417-22. doi: 10.1586/erm.09.32. Review. — View Citation
Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, Talantov D, Timmermans M, Meijer-van Gelder ME, Yu J, Jatkoe T, Berns EM, Atkins D, Foekens JA. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet. 2005 Feb 19-25;365(9460):671-9. — View Citation
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05544123 -
The Treatment Situation of Chinese County Population With Breast Cancer
|
||
Completed |
NCT01881230 -
Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)
|
Phase 2/Phase 3 | |
Withdrawn |
NCT05191004 -
Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC
|
Phase 1/Phase 2 | |
Recruiting |
NCT04626986 -
Comparison of Microwave Ablation With Breast Conserving Surgery for Breast Tumor
|
N/A | |
Completed |
NCT04805775 -
Desflurane and Postoperative Sleep Quality in Patients Undergoing Elective Breast Surgery
|
N/A | |
Recruiting |
NCT03347864 -
68Ga-NOTA-RM26 PET/CT in Breast Tumor Patients
|
Early Phase 1 | |
Completed |
NCT03684408 -
Radiofrequency Chip for Localization of Non-Palpable Breast Lesions
|
N/A | |
Recruiting |
NCT04692818 -
3D Ultrasound Breast Imaging
|
N/A | |
Not yet recruiting |
NCT04825444 -
Clinical Study of Vascular Imaging Evaluation of Computed Tomography Photoacoustic Breast Imaging System
|
||
Recruiting |
NCT05252390 -
NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Withdrawn |
NCT02470819 -
Genomic and Proteomic Profiling Targets Influenced Treatment in Metastatic Breast Cancer
|
N/A | |
Completed |
NCT00859261 -
Two Dimensional (2D) Silicon Transducer-Compression Plates for Breast Ultrasound
|
N/A | |
Active, not recruiting |
NCT05169437 -
Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors
|
Phase 2 | |
Recruiting |
NCT03870620 -
Metastatic Breast Cancer in Austria
|
||
Completed |
NCT05185752 -
Comparative Analysis of Three Locoregional Anesthesia Methods in Breast Tumour Pathology Surgery
|
N/A | |
Recruiting |
NCT04852926 -
Study of the Sexual Health of Patients Treated for Breast Cancer and Followed up in the Observatory of Fertility at Jeanne de Flandre Hospital.
|
||
Recruiting |
NCT06172270 -
Sub-regional Tumor Segmentation Based on CEUS Perfusion Characteristics: Enhancing Breast Tumor Diagnosis
|
||
Recruiting |
NCT04948983 -
The Effect of a Patient Decision Aids for Breast Cancer Screening
|
N/A | |
Not yet recruiting |
NCT06251544 -
TRAIL-R2 and HER2 Bi-Specific Chimeric Antigen Receptor (CAR) T Cells for the Treatment of Metastatic Breast Cancer
|
Phase 1 | |
Terminated |
NCT02364960 -
Targeted Intraoperative Therapy Registry at Bethesda North Hospital (TARGIT)
|